Cidara is developing a new generation of immunotherapeutic agents from its Cloudbreak platform that couple potent drugs to a human antibody fragment. These highly potent, long-acting drug-Fc conjugates (DFCs) are designed to inhibit specific disease targets while simultaneously engaging the immune system.
Cidara’s Cloudbreak platform is a fundamentally new approach to treating and preventing serious diseases such as viral infections and solid tumors. By applying the principles of immuno-oncology, Cidara is creating a new generation of drugs that stably couple a highly potent drug targeting domain, a small molecule or a peptide, to an effector domain, a proprietary variant of a human antibody fragment (Fc). These long-acting, bispecific DFCs are designed to directly inhibit disease targets while simultaneously directing immune-mediated clearance of disease. The two distinct and complementary mechanisms are designed provide potency and selectivity, while also providing extended half-life and attract an immune response against the target virus or cancer cell to maximize disease eradicating activity.
Cidara’s development candidate DFC CD388 is being studied in a Phase 1 clinical trial in partnership with Janssen for universal prevention and treatment of influenza.
Cidara is also advancing preclinical and discovery programs to target solid tumors as well as SARS-CoV-2.